- Home
- MGLD vs MREO Comparison
MGLD vs MREO Comparison
Compare MGLD & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MGLD | MREO |
|---|---|---|
| Founded | 1996 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.8M | 53.4M |
| IPO Year | 2021 | 2017 |
Fundamental Metrics
Financial Performance| Metric | MGLD | MREO |
|---|---|---|
| Price | $1.11 | $0.30 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $1.50 |
| AVG Volume (30 Days) | 4.2K | ★ 912.1K |
| Earning Date | 05-08-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.67 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $34,876,734.00 | $500,000.00 |
| Revenue This Year | N/A | $5,184.20 |
| Revenue Next Year | N/A | $55.51 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.64 | $0.20 |
| 52 Week High | $1.38 | $2.37 |
Technical Indicators
Market Signals| Indicator | MGLD | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 46.01 | 48.22 |
| Support Level | $1.06 | $0.28 |
| Resistance Level | $1.23 | $0.35 |
| Average True Range (ATR) | 0.03 | 0.02 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 1.90 | 44.07 |
Price Performance
Historical ComparisonAbout MGLD The Marygold Companies Inc.
The Marygold Companies Inc is an international holding company focused on acquiring and growing profitable businesses. Its main segments include U.S. Fund Management through USCF Investments, Food Products via Gourmet Foods and Printstock Products in New Zealand, Beauty Products under the Original Sprout brand, and formerly Security Systems through Brigadier, sold in 2025. The majority of revenue comes from fund management. The company operates in the USA, New Zealand, the United Kingdom, and Canada, with the majority of revenue generated from the USA. Its business approach focuses on strengthening financial services, expanding fintech, and managing a diverse portfolio for growth.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).